Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial
The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach 43.6%.
Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer
Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal cancer. The stock was up 12% to $9.73 in pre-market trading.
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Median Overall SurvivalMultiple Patients with Complete Responses (CRs) and/or Partial Response (PR) with 100% Reduction in Target LesionsElraglusib in Combination with GnP Demonstrated a Favorable Risk-Benefit ProfileTrial Continues with Topline Data Anticipated in 1H 2025 CHICAGO and FORT WORTH,
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel.
pancan18h
Research Spotlight – Pancreatic Cancer: A Look Back at 2024
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...
Pancreatic cancer patient survival doubled with high dose of common vitamin, study finds
Researchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in ...
The New York Times1mon
Pancreatic Cancer Surge May Be Less Worrisome Than It Seemed
the sudden rise in pancreatic cancer incidence is largely being driven by another type of tumor — endocrine cancers. They tend to be indolent, taking years or even decades to grow and spread ...
U.S. News & World Report29d
Why Alarm Is Easing Over a Rise in Pancreatic Cancer Among the Young
The first type tends to take years to grow and spread, while the second is typically fast-moving and aggressive. "The increasing incidence of pancreatic cancer in younger Americans is primarily ...
High-dose vitamin C shows promise in pancreatic cancer treatment
High doses of vitamin C, when combined with standard chemotherapy, may significantly extend the life expectancy of patients with advanced pancreatic cancer.